Key statistics
As of last trade Mirum Pharmaceuticals Inc (08D:MUN) traded at 85.00, -2.86% below its 52-week high of 87.50, set on Feb 05, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 85.00 |
|---|---|
| High | 85.00 |
| Low | 85.00 |
| Bid | 82.50 |
| Offer | 86.50 |
| Previous close | 85.00 |
| Average volume | 31.11 |
|---|---|
| Shares outstanding | 51.68m |
| Free float | 50.68m |
| P/E (TTM) | -- |
| Market cap | 5.20bn USD |
| EPS (TTM) | -0.8613 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 07:00 GMT.
More ▼
Press releases
- Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
- Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
- Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum
- Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals
- Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
More ▼
